Together, these data suggest that loss of LZAP represents a new pathway for p53 inactivation in human cancers and that temporary inhibition of LZAP may be a fruitful therapeutic strategy for tumors with mutant p53. The gene discussed is CDK5RAP3; the disease is cancer.